Bismuth-Based Quadruple Therapy versus Metronidazole- Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial
2
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Background/Aims: Clarithromycin resistance is a main factor for treatment failure in the context of Helicobacter pylori infection. However, the treatment regimen for clarithromycin-resistant H. pylori infection has not yet been determined. We aimed to compare the efficacy and cost-effectiveness of 14-day bismuth-based quadruple therapy versus 14-day metronidazole-intensified triple therapy for clarithromycin-resistant H. pylori infection with genotypic resistance. Methods: This was a multicenter, randomized, controlled trial. A total of 782 patients with H. pylori infection examined using sequencing-based clarithromycin resistance point mutation tests were recruited between December 2018 and October 2020 in four institutions in Korea. Patients with significant point mutations (A2142G, A2142C, A2143G, A2143C, and A2144G) were randomly assigned to receive either 14-day bismuth-based quadruple therapy (n=102) or 14-day metronidazole-intensified triple therapy (n=99). Results: The overall genotypic clarithromycin resistance rate was 25.7% according to the sequencing method. The eradication rate of 14-day bismuth-based quadruple therapy was not significantly different in the intention-to-treat analysis (80.4% vs 69.7%, p=0.079), but was significantly higher than that of 14-day metronidazole-intensified triple therapy in the per-protocol analysis (95.1% vs 76.4%, p=0.001). There were no significant differences in the incidence of side effects. In addition, the 14-day bismuth-based quadruple therapy was more cost-effective than the 14-day metronidazole-intensified triple therapy. Conclusions: Fourteen-day bismuth-based quadruple therapy showed comparable efficacy with 14-day metronidazole-intensified triple therapy, and it was more cost-effective in the context of clarithromycin-resistant H. pylori infection.
Abstract
Background/Aims: Clarithromycin resistance is a main factor for treatment failure in the context of Helicobacter pylori infection. However, the treatment regimen for clarithromycin-resistant H. pylori infection has not yet been determined. We aimed to compare the efficacy and cost-effectiveness of 14-day bismuth-based quadruple therapy versus 14-day metronidazole-intensified triple therapy for clarithromycin-resistant H. pylori infection with genotypic resistance. Methods: This was a multicenter, randomized, controlled trial. A total of 782 patients with H. pylori infection examined using sequencing-based clarithromycin resistance point mutation tests were recruited between December 2018 and October 2020 in four institutions in Korea. Patients with significant point mutations (A2142G, A2142C, A2143G, A2143C, and A2144G) were randomly assigned to receive either 14-day bismuth-based quadruple therapy (n=102) or 14-day metronidazole-intensified triple therapy (n=99). Results: The overall genotypic clarithromycin resistance rate was 25.7% according to the sequencing method. The eradication rate of 14-day bismuth-based quadruple therapy was not significantly different in the intention-to-treat analysis (80.4% vs 69.7%, p=0.079), but was significantly higher than that of 14-day metronidazole-intensified triple therapy in the per-protocol analysis (95.1% vs 76.4%, p=0.001). There were no significant differences in the incidence of side effects. In addition, the 14-day bismuth-based quadruple therapy was more cost-effective than the 14-day metronidazole-intensified triple therapy. Conclusions: Fourteen-day bismuth-based quadruple therapy showed comparable efficacy with 14-day metronidazole-intensified triple therapy, and it was more cost-effective in the context of clarithromycin-resistant H. pylori infection.
참고문헌 (23)
- Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use : nationwide survey", Helicobacter, 21, pp.266~278 (2016)
- Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea : a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)
- Hye-Kyung Jung, "한국인 헬리코박터 파일로리 감염 치료 근거 기반 임상진료지침 개정안 2020", Korean Journal of Helicobacter Upper Gastrointestinal Research, 20(4), pp.261~287 (2020), 대한상부위장관ㆍ헬리코박터학회[DOI]
- Pan J, "Is tailored therapy based on antibiotic susceptibility effective? A multicenter, open-label, randomized trial", Front Med, 14, pp.43~50 (2020)
- Horie R, "Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan", Helicobacter, 25, pp.e12698~ (2020)
- Delchier JC, "Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection", Med Mal Infect, 50, pp.492~499 (2020)
- Seo SI, "Helicobacter pylori eradication according to sequencing-based 23S ribosomal RNA point mutation associated with clarithromycin resistance", J Clin Med, 9, pp.54~ (2019)
- Ong S, "Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation : a multicenter randomized controlled trial", Helicobacter, 24, pp.e12654~ (2019)
- Choi YI, "Tailored eradication vs empirical bismuth-containing quadruple therapy for firstline Helicobacter pylori eradication : a comparative, open trial", World J Gastroenterol, 25, pp.6743~6751 (2019)
- Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance", J Infect Dis, 208, pp.1123~1130 (2013)
- De Francesco V, "Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome : benefits and limits", J Antimicrob Chemother, 65, pp.327~332 (2010)
- 김정목, "Gene Mutations of 23S rRNA Associated with Clarithromycin Resistance in Helicobacter pylori Strains Isolated from Korean Patients", Journal of Microbiology and Biotechnology, 18(9), pp.1584~1589 (2008), 한국미생물·생명공학회
- Umegaki N, "Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Japan", J Gastroenterol Hepatol, 15, pp.906~909 (2000)
- Tae-Geun Gweon, "An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment", Gut and Liver, 12(6), pp.648~654 (2018), 거트앤리버 소화기연관학회협의회
- Kim JL, "Empiric versus clarithromycin resistance-guided therapy for Helicobacter pylori based on polymerase chain reaction results in patients with gastric neoplasms or gastric mucosa-associated lymphoid tissue lymphoma : a randomized controlled trial", Clin Transl Gastroenterol, 11, pp.e00194~ (2020)
- Lee JW, "Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance", Helicobacter, 24, pp.e12561~ (2019)
- López-Góngora S, "Systematic review and meta-analysis : susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection", J Antimicrob Chemother, 70, pp.2447~2455 (2015)
- Park CS, "Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance", Am J Gastroenterol, 109, pp.1595~1602 (2014)
- Zhou L, "Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment : a randomized trial", Helicobacter, 21, pp.91~99 (2016)
- Cho JH, "Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients", J Gastroenterol Hepatol, 34, pp.700~706 (2019)
- Papaefthymiou A, "Helicobacter pylori eradication regimens in an antibiotic highresistance European area : a cost-effectiveness analysis", Helicobacter, 25, pp.e12666~ (2020)
- Hwang TJ, "Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea", J Clin Gastroenterol, 44, pp.536~543 (2010)